文献速递糖尿病肥胖与代谢综合征

PCSK9抑制剂依洛尤单抗在伴与不伴糖尿病患者中的心血管安全性与疗效及对血糖和新发糖尿病风险的影响:FOURIER随机对照试验的预设分析

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-09-15

FOURIER预设分析纳入27564例接受他汀治疗的动脉粥样硬化患者,中位随访2.2年。依洛尤单抗在伴与不伴糖尿病患者中均显著降低心血管终点(主要复合终点HR 0.83 vs 0.87,交互P=0.60),未增加新发糖尿病风险(HR 1.05),未恶化血糖。

要点

  • 依洛尤单抗在伴与不伴糖尿病患者中均显著降低主要复合心血管终点,交互作用无统计学意义。
  • 依洛尤单抗未增加新发糖尿病风险(HR 1.05,95%CI 0.94-1.17),糖尿病前期者亦然。
  • 依洛尤单抗组与安慰剂组HbA1c和空腹血糖随时间变化相似。

核心结论

  • 依洛尤单抗在伴与不伴糖尿病患者中均显著降低心血管风险,未增加新发糖尿病风险,亦未恶化血糖。

研究设计与样本

  • FOURIER为随机对照试验,比较依洛尤单抗(每2周140 mg或每月一次420 mg)与安慰剂,纳入27564例接受他汀治疗的动脉粥样硬化患者,中位随访2.2年。
  • 本分析为预设分析,按基线糖尿病状态分组,糖尿病定义基于病史、临床事件委员会病历审核或基线HbA1c≥6.5%(48 mmol/mol)或空腹血糖≥7.0 mmol/L。
  • 事后分析评估基线糖尿病前期(HbA1c 5.7-6.4%[39-46 mmol/mol]或空腹血糖5.6-6.9 mmol/L)患者的血糖与糖尿病风险。

主要发现

  • 基线时11031例(40%)有糖尿病,16533例(60%)无糖尿病(其中10344例糖尿病前期,6189例血糖正常)。
  • 主要复合终点:糖尿病组HR 0.83(95%CI 0.75-0.93;p=0.0008),无糖尿病组HR 0.87(95%CI 0.79-0.96;p=0.0052),交互P=0.60。
  • 关键次要终点:糖尿病组HR 0.82(95%CI 0.72-0.93;p=0.0021),无糖尿病组HR 0.78(95%CI 0.69-0.89;p=0.0002),交互P=0.65。
  • 无糖尿病患者中新发糖尿病风险HR 1.05(95%CI 0.94-1.17),糖尿病前期者HR 1.00(95%CI 0.89-1.13)。
  • 糖尿病组不良事件比例:依洛尤单抗组78.5%(4327/5513) vs 安慰剂组78.3%(4307/5502);无糖尿病组:依洛尤单抗组76.8%(6337/8256) vs 安慰剂组76.8%(6337/8254)。

临床怎么用

  • 作者认为,这些数据提示依洛尤单抗用于动脉粥样硬化患者在伴与不伴糖尿病者中有效且安全。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safety of evolocumab by diabetes status and the effect of evolocumab on glycaemia and risk of developing diabetes. METHODS: FOURIER was a randomised trial of evolocumab (140 mg every 2 weeks or 420 mg once per month) versus placebo in 27 564 patients with atherosclerotic disease who were on statin therapy, followed up for a median of 2·2 years. In this prespecified analysis, we investigated the effect of evolocumab on cardiovascular events by diabetes status at baseline, defined on the basis of patient history, clinical events committee review of medical records, or baseline HbA1c of 6·5% (48 mmol/mol) or greater or fasting plasma glucose (FPG) of 7·0 mmol/L or greater. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina, or coronary revascularisation. The key secondary endpoint was a composite of cardiovascular death, myocardial infarction, or stroke. We also assessed the effect of evolocumab on glycaemia, and on the risk of new-onset diabetes among patients without diabetes at baseline. HbA1c was measured at baseline then every 24 weeks and FPG was measured at baseline, week 12, week 24, and every 24 weeks thereafter, and potential cases of new-onset diabetes were adjudicated centrally. In a post-hoc analysis, we also investigated the effects on glycaemia and diabetes risk in patients with prediabetes (HbA1c 5·7-6·4% [39-46 mmol/mol] or FPG 5·6-6·9 mmol/L) at baseline. FOURIER is registered with ClinicalTrials.gov, number NCT01764633. FINDINGS: At study baseline, 11 031 patients (40%) had diabetes and 16 533 (60%) did not have diabetes (of whom 10 344 had prediabetes and 6189 had normoglycaemia). Evolocumab significantly reduced cardiovascular outcomes consistently in patients with and without diabetes at baseline. For the primary composite endpoint, the hazard ratios (HRs) were 0·83 (95% CI 0·75-0·93; p=0·0008) for patients with diabetes and 0·87 (0·79-0·96; p=0·0052) for patients without diabetes (pinteraction=0·60). For the key secondary endpoint, the HRs were 0·82 (0·72-0·93; p=0·0021) for those with diabetes and 0·78 (0·69-0·89; p=0·0002) for those without diabetes (pinteraction=0·65). Evolocumab did not increase the risk of new-onset diabetes in patients without diabetes at baseline (HR 1·05, 0·94-1·17), including in those with prediabetes (HR 1·00, 0·89-1·13). Levels of HbA1c and FPG were similar between the evolocumab and placebo groups over time in patients with diabetes, prediabetes, or normoglycaemia. Among patients with diabetes at baseline, the proportions of patients with adverse events were 78·5% (4327 of 5513 patients) in the evolocumab group and 78·3% (4307 of 5502 patients) in the placebo group; among patients without diabetes at baseline, the proportions with adverse events were 76·8% (6337 of 8256 patients) in the evolocumab group and 76·8% (6337 of 8254 patients) in the placebo group. INTERPRETATION: PCSK9 inhibition with evolocumab significantly reduced cardiovascular risk in patients with and without diabetes. Evolocumab did not increase the risk of new-onset diabetes, nor did it worsen glycaemia. These data suggest evolocumab use in patients with atherosclerotic disease is efficacious and safe in patients with and without diabetes. FUNDING: Amgen.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28927706. doi:10.1016/S2213-8587(17)30313-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。